

1 **TITLE: Interactive effects of bacterial vaginal colonization and HIV on pregnancy outcomes: A**
2 **Systematic Review and Meta-analysis**

3 Dismas Matovelo^{1*}, Quinn Goddard², Paul Sabuni¹, Benson Kidenya¹, Jennifer Downs^{1,3}, Moke
4 Magoma⁴, Jeremiah Seni¹, Kathleen Helen Chaput²

5 ¹Catholic University of Health and Allied Sciences, Weill Bugando School of Medicine, Mwanza,
6 Tanzania.

7 ²University of Calgary, Cumming School of Medicine, Calgary, Canada

8 ³Center for Global Health, Weill Cornell Medicine, New York, USA

9 ⁴Engender Health, Dar es Salaam, Tanzania

10 Corresponding author: Dismas Matovelo; E-mail: magonza@bugando.ac.tz

11 **Abstract**

12 **Background:** The independent impact of HIV and bacterial vaginal colonization on pregnancy
13 outcomes has been documented and is compounded by the burden of rapidly escalating
14 antimicrobial resistance. However, the interactive effect of HIV and lower genital tract bacterial
15 colonization, on pregnancy outcomes has not been thoroughly studied and is examined in our
16 study.

17 **Methods:** We performed a systematic review and meta-analysis to quantitatively assess the
18 interaction between HIV and vaginal bacterial colonization and associations with birth weight
19 and preterm birth. We searched Ovid MEDLINE, Ovid EMBASE, CINAHL, Scopus, Web of Science,
20 Cochrane Library, African Journals Online, and PubMed databases to identify studies published
21 up to December 31, 2023. We included observational reporting on vaginal colonization with
22 bacterial pathogens stratified by HIV status that reported pregnancy outcomes. We followed the
23 Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines and used a
24 modified Newcastle-Ottawa Scale to assess study quality. Meta-analysis was conducted using
25 random-effects modeling in STATA Version 18. Pooled log-odds ratios were calculated. The study
26 protocol was registered in PROSPERO(CRD42023485123).

27 **Results:** We selected 13 studies, involving 6,073 pregnant women, from 5,807 studies identified.
28 The overall pooled prevalence of bacterial colonization was 26%(95%CI:17.3-37.4). There was no
29 significant effect of HIV status and vaginal colonization on birth weight(OR=1.2, 95%CI:-2.57-2.20,
30 $p=0.88$) and borderline increased odds of preterm birth (OR=2.64, 95%CI:-0.01-1.94, $p=0.05$).
31 There was no significant association between HIV status and bacterial colonization(OR=1.08,

32 95%CI =-0.91-1.07), nor in antimicrobial resistance between pregnant women with HIV and those
33 without.

34 **Conclusion:** Bacterial colonization is prevalent among pregnant women, but there is no clear
35 evidence to suggest that HIV and bacterial colonization interact to affect birth weight or preterm
36 birth. Research with large sample sizes, strict selection criteria, reliable and valid measurement,
37 adequate control for confounding variables, and birthweight and gestational age at delivery
38 assessment as continuous outcomes are still needed to provide robust evidence.

39 **Keywords:** vaginal bacterial colonization, HIV, adverse pregnancy outcomes, preterm birth, low
40 birth weight.

41

42 INTRODUCTION

43 Bacterial genital infections are usually polymicrobial, affecting up to 50% of women during
44 pregnancy, intrapartum, and postpartum, and vary across trimesters due to factors such as
45 hormonal changes, host genetics, behavioural, nutritional, and environment[1-3]. However,
46 despite hormonal changes during pregnancy, vaginal bacterial composition during gestation
47 typically remains relatively stable among pregnant women not living with HIV[4]. In the setting
48 of HIV infection, which is characterized by an increase in pro-inflammatory responses and the
49 release of cytokines, the integrity of the vaginal mucosal epithelium, the primary defence
50 mechanism is disrupted. Due to this loss in integrity of the vaginal mucosal epithelium, the vaginal
51 mucosa in HIV-infected pregnant women is characterized by a diverse microbiota predominantly
52 comprised of anaerobic species[3].

53 The occurrence of lower genital tract infections in pregnancy has significantly been reduced in
54 high-income countries (HICs) in recent decades, due to optimization of surveillance and
55 treatment[5]. However, such routine surveillance for common pathogens colonizing the vagina
56 during pregnancy lack in most Low-Middle Income Countries (LMICs), along with the rapidly
57 escalating burden of antimicrobial resistance (AMR) and variations in worldwide resistance
58 patterns. As a result, empirical treatment has become difficult in LMICs[6, 7].

59 Approximately 70% of people living with HIV are in sub-Saharan Africa, and the global prevalence
60 of HIV among pregnant women is 7.2%[8, 9]. The dual impact of HIV infection and bacterial
61 genital colonization may affect placental development and function, causing low birthweight
62 (LBW), small for gestational age (SGA), intrauterine growth restriction (IUGR), or preterm birth
63 (PTB). Over the past decade it has become clear that although a healthy placenta has no
64 microbiome, it is still susceptible to pathogenic bacterial colonization, commonly group B
65 Streptococcus[10]. Placental bacterial colonization can affect placental development and
66 function, thereby impacting fetal growth and development. Disrupted placental function can lead
67 to SGA, IUGR, preterm labour and birth, rupture of membranes (ROM), chorioamnionitis,
68 neonatal sepsis, and LBW [10, 11]. These factors contribute to a series of short and long-term
69 adverse effects such as neonatal sepsis and delayed child developmental milestones[10, 11].

70 Both HIV and bacterial genital colonization may have an impact on pregnancy outcomes,
71 especially birthweight, which is an important health indicator that has long-lasting impacts on
72 infant and childhood development[11]. Globally, LBW and PTB are common, affecting an
73 estimated 19.8 and 13.4 million births in 2020, respectively, with increased mortality risks
74 particularly in the neonatal period, and long-term adverse health outcomes throughout life[12,
75 13]. However, there is a paucity of evidence on the association between HIV infection, lower
76 genital tract pathogenic bacterial colonization and birth weight and conflicting evidence for

77 associations and potential interactions between bacterial colonization and HIV status with
78 birthweight.

79 Several individual studies attempting to estimate the disease burden of lower genital tract
80 bacterial colonization have reported that regardless of HIV status, *Escherichia coli*, *Klebsiella*.
81 *pneumoniae* and *GBS* are the most common organisms, with a wide prevalence range of 1.5%-
82 73.5%[14, 15]. While some studies report a higher prevalence rate among pregnant women
83 infected with HIV[16], compared with those without, others report no differences[17-19]. To
84 bridge this knowledge gap, we performed a systematic review and meta-analysis to
85 quantitatively assess the prevalence of lower genital tract bacterial infections and their
86 association with pregnancy outcomes in HIV-infected and HIV-uninfected individuals. The results
87 of this study provide insights into designing large prospective studies to decipher the associations
88 between lower genital tract bacteria colonization, HIV infection, and maternal and perinatal
89 outcomes. It will also help healthcare policymakers and various stakeholders ideally, seeking to
90 standardize protocols for medical care and screening in this vulnerable population, with the
91 ultimate goal of reducing associated adverse maternal and perinatal outcomes.

92 **METHODS**

93 **Objective:** The current review aimed to examine the interactive effects of lower genital tract
94 bacterial colonization in pregnancy and HIV infection on the primary outcomes of birthweight
95 and preterm birth. The secondary outcomes were intrauterine growth restriction (IUGR) and
96 small for gestation age (SGA), as well as assessed the prevalence of antimicrobial resistance
97 (AMR) among HIV-infected vs -uninfected pregnant women as a tertiary outcome. This review
98 was conducted following PRISMA guidelines (S2 Appendix) [20] and was registered with the
99 International Prospective Register of Systematic Reviews (PROSPERO)[21], registration number
100 CRD42023485123, December 2023.

101 **Search Strategy:** We identified studies using electronic research databases and hand-searching
102 methods. The comprehensive search strategy was developed in consultation with a research
103 librarian and reviewed by two perinatal researchers (S1 Appendix). Our controlled vocabulary
104 search included the following exploded keywords: *Vaginitis*, "*Genital Diseases, Female*",
105 "*Reproductive Tract Infections*", *vagina*, *bacteria*, *Escherichia coli*, "*Klebsiella pneumoniae*",
106 "*streptococcal infections*", *HIV*, *HIV Seropositivity*, *HIV Infections*, *HIV Seronegativity*, *Pregnancy*,
107 *Pregnant Women*, *Pregnancy Trimester*, *Third*, and *pregnancy outcome*.

108 We applied the search strategy in MEDLINE (Ovid), EMBASE (Ovid), CINAHL, Scopus, Web of
109 Science and the Cochrane Library to identify studies published regardless of year. We also
110 searched African Journals Online and PubMed databases for additional publications and used
111 Web of Science, Google and Google Scholar to search for grey literature. We modified indexing

112 terms such as Medical Subject Headings (MESH) or field tags according to each database and
113 linked searches using “AND” and “OR” Boolean operator terms as required. We hand-searched
114 by scanning references, “cited-by”, and “similar articles” lists for eligible studies. No filters were
115 applied.

116 **Eligibility criteria:** We initially included all quantitative observational studies that reported the
117 prevalence of bacterial vaginal colonization published in English in peer-reviewed journals.
118 Observational studies were included in the meta-analysis, that employed cohort, case-control, or
119 cross-sectional designs. We included grey literature and published abstracts for a narrative
120 summary in the review.

121 Eligible studies involved pregnant women of any age who were tested for vaginal bacterial
122 colonization at any point during their gestation. Studies must have had an exposure arm with
123 pregnant women with HIV infection and a control arm with those without HIV. Studies must have
124 measured birth weight and/or preterm birth as a pregnancy outcome, to document the
125 differences in associations between vaginal bacterial colonization and birth weight among
126 pregnant women with and without HIV. The outcomes involved aggregate counts for preterm
127 birth (< 37 weeks completed gestation) and low birth weight (< 2500g).

128 **Study selection:** We used Covidence software to collate our initial search results and remove
129 duplicates before screening. Two independent authors (DM and QG) screened titles and abstracts
130 of each article and assigned a ‘yes’, ‘no’, or ‘maybe’ to their eligibility for inclusion. Studies
131 marked as “yes” or “maybe” underwent a full-text review, during which reasons for exclusion
132 were documented. Any conflicts in decision-making were resolved by a third author (KHC). The
133 Kappa index of the inter-observer agreement for title/abstract and full-text selection was high
134 (0.96 and 0.73, respectively) as calculated by Covidence.

135 **Data Extraction and Critical Appraisal:** Authors (DM and QG) conducted data extraction using
136 Covidence, which was then exported into Microsoft Excel 2023. We extracted the following
137 variables from the articles: a) first author’s name, b) publication year, c) region/country, d) study
138 type/design, e) type of sample collected, f) sample size, g) sampling method, h) the prevalence
139 of vagina colonization, i) the microorganisms involved, j) pregnancy outcomes, and k) any other
140 results relevant to primary and secondary outcomes (if applicable). Two authors (DM and QG)
141 conducted the data extraction independently. Any discrepancies that emerged were resolved by
142 a third individual (KHC). If desired data were available for extraction, we contacted authors a
143 minimum of three times between January and June 2024 to obtain missing data points. Studies
144 were excluded from the meta-analysis if the authors were unreachable or unable to share the
145 required data.

146 **Quality assessment:** We used the modified Newcastle-Ottawa Scale (NOS) for quality assessment
147 since all eligible studies were observational designs[22]. We adapted the tool by adding topic-
148 specific criteria to make it more relevant to an epidemiological context. Specifically, we added
149 criteria for controlling additional confounders (such as co-morbidities), defining key variables
150 (such as vaginal colonization), and reporting sample, exposure, and control group details.

151 Quality assessment was performed by the first (DM) and second (QG) authors, and verified by
152 the senior author (KHC). The NOS scale consists of eight sections that evaluate an article based
153 on selection criteria, comparability, exposure assessment, and outcomes. Each included study
154 received a score corresponding to the number of quality criteria satisfied, with scores of 0-5
155 considered low quality, 6-7 considered moderate quality, and 8-10 considered high quality. We
156 included all articles in the systematic review but only studies with a minimum score of 6 and
157 above were included in the meta-analysis.

158 **Data analysis:** A narrative analysis was performed to summarize the characteristics of the
159 included studies. We quantified the pooled interactive effect of bacterial vaginal colonization and
160 HIV on pregnancy outcomes, as well as the association between HIV and bacterial colonization,
161 using random-effects maximum likelihood forest plots to calculate log-odds ratios (OR) and their
162 corresponding 95% confidence intervals. We further quantified the interaction using Cochrane's
163 Q value and Higgins I-squared (I^2)[23], with a continuity correction of 0.5 for insufficient cell
164 sizes[23]. We categorized I^2 values of 0–40% as low heterogeneity; 50–70% as moderate
165 heterogeneity, and >70% as high heterogeneity[22]. The heterogeneity of studies reporting
166 primary outcomes was further assessed using a Galbraith Plot with 95% confidence intervals.
167 Publication bias was represented graphically using a contour-enhanced funnel plot. We
168 conducted all analyses using Stata version 17.0.

169 **Results**

170 We initially identified 7,005 identified studies (Medline = 981, Embase = 1,137, Web of Science
171 = 276, CINAHL = 4,075, Scopus = 459, Cochrane = 61, and grey literature (ProQuest) = 14; 1,198
172 duplicates were excluded). The first and second authors screened the 5,805 remaining
173 abstracts, deeming 5,719 irrelevant. This left 86 studies for assessment. Two studies were
174 identified through hand-searching reference lists and were included in a full-text review (S1
175 Figure).

176 S1 Figure: PRISMA flowchart diagram of the study selection

177 The two authors had high inter-rater reliability (proportionate agreement = 0.97) and resolved
178 177 conflicting assessments through consensus. After a full-text review of 88 studies, 13 studies
179 that met the inclusion criteria were included in the systematic review (Table in S1 Table). All
180 identified studies were rated as 7 or higher by the first and second authors on the modified NOS.

181 Therefore, no studies were excluded from the meta-analysis based on quality assessment (S2
182 Table).

183 Since the majority of the included studies did not report all data points required for meta-
184 analysis, we contacted the authors from all studies to request additional data. All included studies
185 were conducted between 2006 and 2023 and published online between 2017 and 2023. Of the
186 studies selected, four were cross-sectional, seven were cohort studies, and two were case-
187 control studies. All except three were conducted in Africa. We found no other published
188 systematic reviews on this topic.

189 The overall sample size of all included studies was 6,073 participants, with individual study
190 sample sizes ranging from 75 to 1,857. The prevalence of vaginal bacterial colonization ranged
191 from 3.3% to 69.3% (Table in S1 Table). Testing and diagnostic criteria for bacterial colonization
192 varied (S2 Table).

193

194

195 S1 Table: Characteristics of the included studies

| s/ n | Author Name | Publicatio n Year | County | Study Design | Total (N) | HIV Status | | Colonizati on (%) | 95%CI | Type of bacteria |
|----------------|----------------------------------|----------------------|-----------------------------------|-------------------------|--------------|-------------------|-------------------|-------------------------|--------------------|--|
| | | | | | | HIV+ n (%) | HIV- n (%) | | | |
| 1 | Madrid., et al [24] | 2018 | Mozambiqu e | Cohort | 320 | 117(36.6) | 203(64.4) | 120(37.5) | 32.3%-42.9% | <i>GBS & E. coli</i> |
| 2 | Nyemba., et al [25] | 2022 | South Africa | Cohort | 619 | 486(78.5) | 133(21.5) | 198(32.0) | 27.6%-34.9% | <i>Chlamydia trachomatis, Neisseria gonorrhoea</i> |
| 3 | Gudza- Mugabe., et al [26] | 2020 | Zimbabwe | Cohort | 356 | 42(11.8) | 314(88.2) | 88(24.7) | 20.4%-29.3% | <i>Bacterial vaginosis</i> |
| 4 | Njoku., et al [27] | 2018 | Nigeria | Cross- section al | 168 | 84(50.0) | 84(50.0) | 18(10.7) | 6.4%-15.9% | <i>Group B Streptococcus</i> |
| 5 | Price., et al [28] | 2021 | Zambia | Cohort | 363 | 85(23.4) | 278(76.6) | 221(60.9) | 55.8%-65.8% | <i>Bacterial vaginosis</i> |
| 6 | Biobaku., et al [29] | 2017 | Nigeria | Cross- section al | 198 | 67(33.8) | 131(66.2) | 36(18.2) | 13.1%-23.9% | <i>Group B Streptococcus</i> |
| 7 | Smullin., et al [30] | 2020 | South Africa | Cohort | 197 | 92(46.7) | 105(53.3) | 35(17.8) | 12.7%-23.4% | <i>Mycoplasma genitalium</i> |
| 8 | Short., et al [31] | 2020 | UK | Cohort | 75 | 53(54.6) | 22(45.4) | 52(69.3) | 58.4%-79.3% | <i>Bacterial vaginosis</i> |
| 9 | Makinde., et al [32] | 2022 | Nigeria | Cross- section al | 244 | 122(50.0) | 122(50.0) | 8(3.3) | 1.4%-5.9% | <i>Group B Streptococcus</i> |
| 10 | Morgan., et al [33] | 2023 | United States of America | Case- control | 225 | 75(33.3) | 150(66.7) | 77(34.2) | 28.2%-40.6% | <i>Group B Streptococcus</i> |
| 11 | Ravindran, et al [34] | 2021 | Kenya | Cohort | 1244 | 10(0.01) | 1234 (99.99) | 302(24.3) | 21.9%-26.7% | <i>Chlamydia trachomatis, Neisseria gonorrhoea</i> |
| 12 | Gray, et al [35] | 2011 | Malawi | Case- control | 1857 | 402 (21.7) | 1454 (78.3) | 390 (21.0) | 19.2%-22.9% | <i>Group B Streptococcus</i> |
| 13 | El Beitune et al [36] | 2006 | Brazil | Cross- section al | 207 | 101 (48.8) | 106 (51.1) | 35 (16.9) | 12.1%-22.3% | <i>Group B Streptococcus</i> |
| Overall | | | | | 6073 | 1736(28.6) | 4336(71.4) | 1542(26.0) | 17.3%-37.4% | |

196

197

198 S2 Table: Distribution of vaginal bacterial colonization among pregnant women

| <i>Author name</i> | <i>Total (N)</i> | <i>Lab Method</i> | <i>Bacteria</i> | <i>HIV+ n (%)</i> | <i>95% CI</i> | <i>HIV- n (%)</i> | <i>95% CI</i> | <i>NOS</i> |
|----------------------------|------------------|------------------------|--|-------------------|---------------|-------------------|---------------|------------|
| <i>Madrid (2018)</i> | 120 | Culture | <i>E.coli</i> | 44(36.7) | 28.2%-45.5% | 76(63.3) | 54.5%-71.8% | 8 |
| <i>Nyemba (2022)</i> | 198 | Culture | <i>Chlamydia trachomatis, Neisseria gonorrhoea</i> | 163(82.3) | 76.7%-87.3% | 35(17.7) | 12.7%-23.3% | 8 |
| <i>Gudza-Mugabe (2020)</i> | 88 | PCR & DNA Sequencing | <i>Bacterial vaginosis</i> | 18(20.5) | 12.6%-29.6% | 70(79.5) | 70.4%-87.4% | 7 |
| <i>Njoku (2018)</i> | 18 | Culture | <i>Group B Streptococcus</i> | 13(72.2) | 48.9%-90.9% | 5(27.8) | 9.1%-51.1% | 8 |
| <i>Price (2021)</i> | 221 | Metagenomic Sequencing | <i>Bacterial vaginosis</i> | 85(38.7) | 32.1%-45.0% | 136(61.5) | 55.0%-67.9% | 8 |
| <i>Biobaku (2017)</i> | 36 | Culture | <i>Group B Streptococcus</i> | 13(36.1) | 21.1%-52.6% | 23(63.9) | 47.4%-78.9% | 10 |
| <i>Smullin (2020)</i> | 35 | Culture | <i>mycoplasma genitalium</i> | 22(62.9) | 46.1%-78.2% | 13(37.1) | 21.8%-53.9% | 8 |
| <i>Short (2020)</i> | 52 | DNA Sequencing | <i>Bacterial vaginosis</i> | 42(80.8) | 68.8%-90.5% | 10(19.2) | 9.5%-31.2% | 7 |
| <i>Makinde (2022)</i> | 8 | Culture | <i>Group B Streptococcus</i> | 4(50.0) | 15.3%-84.7% | 4(50.0) | 15.3%-84.7% | 8 |
| <i>Morgan (2023)</i> | 77 | Culture | <i>Group B Streptococcus</i> | 31(40.3) | 29.5%-51.5% | 46(59.7) | 48.5%-70.5% | 7 |
| <i>Ravindran (2021)</i> | 302 | Culture | <i>Chlamydia trachomatis, Neisseria gonorrhoea</i> | 4(0.01) | 0.0%-3.0% | 296(99.99) | 97.0%-99.7% | 8 |
| <i>Gray (2011)</i> | 390 | Culture | <i>Group B Streptococcus</i> | 77(19.4) | 15.9%-23.8% | 313(21.7) | 76.2%-84.1% | 7 |
| <i>El Beitune (2006)</i> | 207 | culture | <i>Group B streptococcus</i> | 20(19.8%) | 40.3%-73.2% | 15(14.1%) | 26.8%-59.7% | 7 |

199

200 **Narrative analysis**

201 No clear pattern of association between HIV, bacterial colonization, and low birth weight was
 202 observed in the included studies. For instance, Makinde *et al*[32] found no association between
 203 vaginal colonization and HIV status regarding low birth weight. Potentially, the very low
 204 prevalence of GBS within their sample (8/244), leading to low power in detecting an effect may
 205 explain the overall findings of this study. Similarly, Gudza-Mugabe *et al*[26] found no interaction

206 between vaginal microbiota and HIV positivity in determining birth outcomes. In contrast,
207 Nyemba *et al*[25] found that the presence of *C. trachomatis* and *N. gonorrhoea* at the first
208 antenatal care (ANC) visit in individuals with HIV leads to an increased risk of an adverse birth
209 outcome. It is important to note that the the bacterial species examined varied across studies
210 (i.e., *GBS*, *C. trachomatis*, *N. gonorrhoeae*).

211 Results for preterm birth were more consistent across the included studies. Nyemba *et al*[25],
212 Smullin *et al*[30], and Short *et al*[31] all found an elevated risk of preterm birth in analyzing the
213 interaction between vaginal colonization and HIV status. However, Gudza-Mugabe *et al*[26] and
214 Price *et al*[28] found that individuals with HIV infection were more likely to give birth
215 prematurely, regardless of vaginal microbiota, suggesting that the relationship between HIV
216 status and preterm birth was not modified by bacterial colonization. Ravindran *et al*[34] found
217 that incident HIV infection, as well as *C. trachomatis* and *N. gonorrhoeae* infection, all
218 independently increased the risk of PTB. El Beitune *et al*[36] found no significant difference in the
219 prevalence of GBS carriage between HIV-positive and HIV-negative participants as well as no
220 significant difference in gestational age and birthweight of infants born to HIV-positive mothers
221 compared with those born to HIV-negative mothers. The study did not stratify birth outcomes by
222 *GBS* status. Since most of these papers did not stratify by bacterial colonization status and HIV
223 status, the data included in our meta-analysis were obtained directly from the authors upon
224 request.

225 Benedetto *et al*[37] tested for BV as well as *C. trachomatis*, but did not stratify birth outcome by
226 HIV status with regards to colonization. The study found that cervicovaginal infections increased
227 the chance of preterm delivery. Foessleitner *et al*[38] investigated vaginal dysbiosis and BV in
228 HIV-positive and HIV-negative women. While preterm birth was equally likely regardless of HIV
229 status, it was found that HIV-positive women were more likely to develop dysbiosis or BV.
230 Govender *et al*[39] analyzed the prevalence of genital mycoplasmas, ureaplasmas, and
231 *Chlamydia trachomatis* to HIV status. There was no association between HIV status and bacterial
232 colonization, as well as preterm delivery and colonization.

233 Several additional studies examined our variables of interest, but a lack of access to the original
234 dataset (e.g. destruction or loss of data) meant we were unfortunately not able to include them
235 in our meta-analysis. Zenebe *et al*[40] documented STI status during pregnancy but did not
236 analyze the interaction between STI and HIV status on pregnancy outcomes. Looking at HIV
237 individually, they found that the mean birth weight was higher in babies born to HIV-uninfected
238 women, and women with HIV were more likely to give birth to a LBW infant than those without.
239 Joachim *et al*[41] examined GBS colonization as well as HIV status, finding no significant
240 association between infant birthweight and GBS carriage, but did not examine differences by HIV
241 status. Seale *et al*[42] found that women with GBS had a higher chance of stillbirth, but equal

242 likelihood of very preterm birth and very low birthweight than those without. It was found that
243 GBS carriage was reduced overall in women with HIV, but that women with HIV were more likely
244 to have more virulent CC17 GBS. Temmerman *et al*[43] tested for BV, *C. trachomatis*, *N.*
245 *gonorrhoeae*, as well as HIV. It was found that mothers with HIV were more likely to give birth to
246 small for gestational age infants. Madrid *et al*[24] tested for *Group B Streptococcus* and found
247 that mothers with HIV were at no higher risk of *GBS* colonization than those without. Morgan *et*
248 *al*[33] found that HIV-positive individuals had a higher chance of preterm birth, but that the
249 likelihood of *GBS* colonization did not differ between individuals with and without HIV.

250 Only one study, Gudza-Mugabe *et al*[26], analyzed small for gestational age (SGA), and found no
251 difference in SGA between mothers with and without HIV. None of the included studies analyzed
252 intrauterine growth restriction.

253 **Meta-Analysis**

254 **Primary Outcomes:** Of the studies with adequate data to be included in the meta-analysis, five
255 examined low birth weight as an outcome, with an overall sample of 3,520 individuals, 784
256 (22.2%) of whom had bacterial colonization and 1,284 (36.4%) were pregnant women with HIV
257 infection. Six studies examined preterm birth, with a total sample of 5,164 individuals, 1,356
258 (26.3%) of which had bacterial colonization and 1,372 (26.6%) were pregnant women with HIV.

259 *Low Birthweight:* We observed no significant interactive effect between HIV status and vaginal
260 bacterial colonization on low birth weight (log OR= 0.19, 95% CI= -2.57,2.20, equivalent OR=1.21,
261 $p = 0.88$) and a high degree of heterogeneity between the studies ($I^2 = 88.73\%$; $Q = 19.84$, $p = 0.00$),
262 indicating low reliability for the pooled estimate (S2 Figure).

263 S2 Figure: Interactive effect of HIV and bacterial colonization on birthweight.

264 *Preterm Birth:* Overall, we found a borderline-significant increased log-odds of preterm birth
265 among individuals with HIV and vaginal bacterial colonization, compared to those without either
266 (log OR= 0.97, 95% CI=-0.01, 1.94, $p = 0.05$; equivalent OR: 2.64, $p = 0.05$). Moderate heterogeneity
267 was observed between the included studies ($I^2 = 53.76\%$; $Q = 16.78$, $p = 0.02$), indicating
268 moderate reliability of the estimate. One study [34] reported a log-OR less than 0 (indicating the
269 protective effect of HIV and Colonization), while the majority of studies (75%) trended toward
270 increased odds of preterm birth with HIV and bacterial colonization compared to no HIV or
271 colonization (S3 Figure).

272 The methods of calculating gestational age varied, potentially impacting the estimate of preterm
273 birth. Three studies [25, 26, 35] used an estimate of last menstrual period (LMP), one study [28]
274 used ultrasound dating, and one study [34] employed a combination of ultrasound, LMP and
275 fundal height. The two remaining studies [30, 31] did not specify the method of GA calculation.

276 S3 Figure: Interactive effect of Hiv and bacterial colonization on preterm birth.

277 **Heterogeneity**

278 We lacked enough studies in the pooled analysis of low birthweight to effectively evaluate
279 heterogeneity or publication bias graphically for this outcome. The Galbraith plot of preterm birth
280 studies confirms overall low-moderate heterogeneity, with all 8 studies lying within the 95% CI
281 region (S4 Figure). The regression line significantly deviates from the null-effect line, with 75% of
282 the studies positioned above the no-effect line.

283 S4 Figure: Galbraith plot of precision in studies examining low birthweight

284 **Publication Bias**

285 The included studies produce a right-skewed, asymmetrical funnel (S5 Figure), suggesting the
286 presence of publication bias. This bias likely stems from the underreporting of null or protective
287 findings, potentially leading to an overestimation of the effect in the included studies. Therefore,
288 although 7 out of 8 studies lie within the 90% confidence interval, these findings should be
289 interpreted cautiously due to the relatively low number of studies included in this assessment
290 (<10).

291 S5 Figure: Publication bias contour-enhanced funnel plot

292 **Secondary Outcomes:** The birth outcomes examined in the included studies varied considerably,
293 and we had insufficient data to generate meaningful pooled estimates for our secondary
294 outcomes of intrauterine growth restriction (IUGR), and small for gestational age (SGA). This was
295 defined as a birth weight of less than the 10th percentile for gestational age.

296 **Tertiary Outcome:** In assessing antimicrobial resistance (AMR), we found that six different types
297 of bacterial isolates were examined in the included studies, with the highest pooled prevalence
298 being bacterial vaginosis (33.9%), examined in three studies. Six of the included studies tested
299 for Group B Streptococcus (GBS) which had a pooled prevalence of 20.2%. Other bacterial species
300 were less commonly examined (S3 table). All studies testing AMR evaluated *GBS*, facilitating
301 meaningful pooled estimates of the association between HIV and *GBS* in terms of AMR.

302

303

304

305

306 S3 Table: Vaginal colonization bacterial isolate types

| <i>Bacterial isolates</i> | <i>No. of studies</i> | <i>Total N</i> | <i>Cases</i> | <i>Prevalence, 95% CI</i> |
|--|-----------------------|----------------|--------------|---------------------------|
| <i>Group B Streptococcus</i> [27, 29, 32, 33, 35, 36] | 6 | 3129 | 632 | 20.2%, 18.8%-21.6% |
| <i>Mycoplasma genitalium</i> [30] | 1 | 197 | 35 | 17.8%, 12.7%-23.4% |
| <i>Bacterial vaginosis</i> [26, 28, 31] | 3 | 794 | 269 | 33.9%, 30.6%-37.2% |
| <i>Neisseria Gonorrhoea</i> [25] | 1 | 619 | 35 | 5.7%, 4.0%-7.6% |
| <i>Chlamydia trachomatis</i> [25] | 1 | 619 | 158 | 25.5%, 22.2%-29.0% |
| <i>Escherichia coli</i> [24] | 1 | 320 | 52 | 16.2%, 12.4%-20.5% |
| <i>Any STI in pregnancy</i> [25, 30] | 2 | 816 | 311 | 38.1%, 34.8%-41.5% |
| <i>Chlamydia trachomatis & Neisseria gonorrhoea</i> [34] | 1 | 1244 | 302 | 24.3%, 21.9%-26.7% |

307

308 S6 Figure: Association between HIV status and Bacterial Colonization

309 There was no significant association between HIV status and bacterial colonization across
 310 included studies (log-OR=0.08 [-0.91, 1.07]; equivalent OR=1.08) (S6 Figure). Likewise, we found
 311 no statistically significant difference in log odds of AMR between HIV-positive and HIV-negative
 312 individuals for each antibiotic examined for resistance (Ampicillin: log-OR=0.47[-0.94, 1.87];
 313 equivalent OR=1.60, Ceftriaxone: log-OR=0.28[-1.77, 2.33]; equivalent OR=1.32, Clindamycin:
 314 log-OR=0.48[-1.28, 2.24], equivalent OR=1.61, Erythromycin: logOR=1.14[-0.83, 3.11], equivalent
 315 OR=3.12, Penicillin: log-OR=0.42 [-0.94, 1.77], equivalent OR=1.42). Heterogeneity was low to
 316 moderate for most antibiotics, except for erythromycin ($I^2=75.79$). (S7 Figure: A-E) We were
 317 unable to pool proportions of antimicrobial resistance across antibiotic types, due to aggregate
 318 reporting of AMR, and lack of individual participant data.

319 **A.**

320 **B.**

321 **C.**

322 **D.**

323 **E.**

324 S7 Figure: Pooled log odds of AMR among those with and without HIV, by antibiotics

325

326

327 Discussion

328 This systematic review and meta-analysis found no significant interactive effects between HIV
329 and vaginal bacterial colonization on low birthweight in the included studies (OR=1.21, p=0.88).
330 We found the odds of preterm birth among those with HIV and bacterial colonization was 2.64
331 times greater than those without HIV or colonization, albeit borderline non-significant (OR=2.64,
332 $p=0.05$). The majority of studies tended toward increased odds of preterm birth with HIV and
333 colonization, preterm birth remains a rare outcome, and even with pooling study results, we may
334 have lacked the statistical power to adequately assess the effect. Unfortunately, due to both data
335 availability limitations and limitations in the available data, we could not model the pooled effect
336 on gestational age or birth weight outcomes as continuous variables, which would have improved
337 statistical power. Future studies should report incidences of both continuous and categorical
338 outcome measures to allow for a more nuanced assessment of this relationship.

339 We found no previous systematic review or meta-analysis which has assessed the potential
340 interactive relationship between HIV status, vaginal bacterial colonization and LBW, though when
341 assessed separately, systematic reviews and meta-analyses show that HIV-exposed neonates are
342 at higher risk for GBS neonatal disease[44], and that low birth weight is more prevalent in
343 neonates born from women living with HIV infection[45]. Our findings regarding preterm birth
344 are similar to those from previous systematic review and meta-analyses that demonstrated
345 increased odds of preterm birth among individuals with HIV and vaginal bacterial colonization
346 compared to those without[45]. Results from Ravindran *et al*[34] study of a decreased risk of
347 preterm birth in HIV-positive individuals with colonization differed from other studies. However,
348 this finding may be attributable to the small sample size of HIV-positive participants in this study
349 ($n = 10$) and the corresponding higher likelihood of type II error, as well as the fact that they did
350 not recruit based on HIV status, and only retained incident cases of HIV in their originally HIV-
351 negative cohort. Although there was only moderate heterogeneity among our included studies,
352 varying patterns of pathogenic bacteria colonizing the lower genital tract, and the fact that
353 *bacterial vaginosis* is a clinical syndrome caused by a group of bacterial species, rather than a
354 single pathogen type, may have contributed to the observed heterogeneity in studies.
355 Additionally, some methodological differences in the studies could contribute to our results,
356 including differential methods and criteria for testing for bacterial colonization among groups
357 with and without HIV, differing methods of defining preterm birth, and selection and inclusion
358 criteria.

359 We also found that the overall odds of bacterial colonization did not differ significantly between
360 those living with HIV and those without. This finding is congruent with a systematic review and
361 meta-analysis conducted by Cools *et al.* which showed no difference between HIV status and
362 rectovaginal colonization[44]. Our meta-analysis included 13 studies, however, the high degree

363 of heterogeneity between studies limits the reliability of this estimate. Further, we found
364 moderate to high risk of bias in most studies included in our analysis, due to methodological
365 limitations. However, few of these studies were designed to assess the association between HIV
366 status and bacterial colonization as a primary outcome. Future prospective cohort studies with
367 strong selection and recruitment strategies, along with adequate confounding control in the
368 analysis are necessary to confirm whether HIV status impacts the odds of bacterial colonization
369 in pregnancy. Similarly, we did not observe a significant difference in the odds of antimicrobial
370 resistance (AMR) among those living with HIV and those without. However, the sample sizes for
371 each antibiotic were small, and due to a lack of individual-level data, we were unable to pool the
372 analysis across antibiotic types, which limited statistical power. Although the specific antibiotics
373 to which resistance exists is important to understand, future studies should also consider the
374 inclusion of an analysis of whether pregnant individuals with colonization are resistant to one or
375 more antibiotics, to allow an examination of the association between HIV status and resistance.
376 In a meta-analysis conducted in the general population among people living with HIV, those with
377 HIV were more likely to be colonized with resistant bacterial strains than people without and
378 there was an increased risk of AMR in those living with HIV, across a range of bacterial pathogens
379 and in multiple drug classes[46]. However, it remains unclear if similar patterns persist during
380 pregnancy. Moreover, bacteria colonizing the lower genital tract in high-income countries (HICs)
381 tend to be predominantly Gram-positive. In Low and Middle-Income Countries (LMICs), Gram-
382 negative bacteria are predominant and are more highly associated with neonatal sepsis and
383 mortality, highlighting a need for further research taking into account this geographical context.

384 Although this systematic review and meta-analysis presents up-to-date global evidence on the
385 prevalence of vaginal bacterial colonization and pregnancy outcomes, it is not without
386 limitations. The majority of the included studies are from Africa where the prevalence of HIV
387 infection is high (60% of the HIV-infected population is in Africa). Comparatively, there is a lack
388 of studies originating from Asia, Europe, and North and South America. The generalizability of
389 the findings is therefore limited to African populations, as the overall sample is not representative
390 of a global population. Further, most included studies recruited participants and/or laboratory
391 samples through hospitals or from mothers who presented for routine ANC or delivery at tertiary
392 hospitals. This could potentially skew the estimated prevalence towards urban settings and
393 underestimate the associations that might exist in rural areas or smaller local health centres
394 serving individuals of a more vulnerable socioeconomic status. The risk of antimicrobial-resistant
395 organisms likely differs in these tertiary hospitals compared to rural settings and may be higher
396 due to greater exposure to antimicrobials in people seeking care at tertiary hospitals.

397 One of the strengths of this study is the inclusion of studies examining direct vaginal colonization,
398 whereas several previous studies evaluated rectal colonization only, meaning previous evidence
399 may include pathogens that are not present in the lower genital tract, and thus may not influence

400 pregnancy to the same extent[47, 48]. Although the large overall sample size of included studies
401 in our review is a strength, the limited number of studies with complete data for inclusion in the
402 meta-analyses of each outcome coupled with the moderate to high heterogeneity of studies
403 limits the reliability of estimates, and our findings should be interpreted with caution. A further
404 limitation of our findings is that there is likely some publication bias toward those with significant
405 findings in the direction of elevated odds of adverse outcomes, which further limits the reliability
406 of our findings.

407 The result of this meta-analysis indicates that there is still no clear evidence of whether HIV
408 infection and bacterial colonization interact to affect low birth weight or preterm birth. There is
409 still no global consensus on routine screening of pregnant women for lower genital tract
410 pathogenic bacterial colonization, and the variations in methods used across the included studies
411 are likely diminishing the reliability of our findings. Working toward a standardized vaginal
412 bacterial screening during pregnancy, regardless of HIV status, could act to improve the
413 identification of bacterial infections and potentially reduce any associated adverse outcomes.
414 Further research conducted with large sample sizes, strong selection criteria, reliable and valid
415 measurement, and adequate control for confounding variables, along with the assessment of
416 birthweight and gestational age at delivery as continuous outcomes are desirable to strengthen
417 the evidence in this area of research.

418 **Abbreviations:** AMR-Antimicrobial Resistance; AMSTAR-Assessing the Methodological Quality of
419 Systematic Reviews; ANC-Antenatal Care; CINAHL-Cumulative Index to Nursing and Allied Health
420 Literature; CMA-Comprehensive Meta-Analysis; CI- Confidence Interval; HICs- High-Income
421 Countries; HIV-Immunodeficiency Virus; IUGR-Intrauterine Growth restrictions; LBW-Low Birth
422 Weight; LMICs-Low-Middle Income Countries; MESH-Medical Subject Headings; OR-Odds ratio;
423 NIH-National Institutes of Health; NOS-New Castle-Ottawa Scale; PCR-Polymerase Chain
424 Reaction; PRISMA-Preferred Reporting Items for Systematic Reviews and Meta-Analyses; SGA-
425 Small for Gestation; SD-Standard Deviation; SSA-Sub-Saharan Africa.

426 **Contributions:** DM and KHC developed the protocol and were involved in the design, selection
427 of study, data extraction, quality assessment, statistical analysis, results interpretation and
428 development of the initial and final drafts of the manuscript; JS, JD, and MM conceived the
429 project, designed the study and did several reviews of the manuscripts; DM, QG and KHC were
430 involved in screening, quality assessment, data extraction, statistical analysis and revising
431 subsequent manuscript drafts; PS and BK were involved in data analysis, synthesis and review of
432 the manuscript. All authors read and approved the final draft of the manuscript.

433 **Ethics approval:** Ethical approval was not required since this study relied solely on published
434 data. However, permission for publication was sought from the CUHAS/BMC Research & Ethical
435 Committee (CREC).

436 **Data availability:** The data analyzed during the current systematic review and meta-analysis are
437 available and made public (S3 Appendix).

438 **Acknowledgements:** We would like to thank the staff of the University of Calgary, particularly
439 Sophie Petit from the Indigenous, Local & Global Health (ILGH) office and Dianne Lorenzetti from
440 the University Library, for their assistance with developing the search strategy. We also extend
441 our gratitude to all the authors of the studies included in this systematic review and meta-
442 analysis.

443 References


- 444 1. Tumuhamy, J., Steinsland, H., Tumwine, J.K., Namugga, O., Mukunya, D., Bwanga, F., et al.,
445 *Vaginal colonisation of women in labour with potentially pathogenic bacteria: a cross sectional*
446 *study at three primary health care facilities in Central Uganda.* BMC infectious diseases, 2020.
447 **20**(1): p. 98.
- 448 2. Sweeney, E.L., Kallapur, S.G., Gisslen, T., Lambers, D.S., Chougnet, C.A., Stephenson, S.A., et al.,
449 *Placental infection with Ureaplasma species is associated with histologic chorioamnionitis and*
450 *adverse outcomes in moderately preterm and late-preterm infants.* The Journal of infectious
451 diseases, 2016. **213**(8): p. 1340-1347.
- 452 3. Juliana, N.C., Peters, R.P., Al-Nasiry, S., Budding, A.E., Morr , S.A. and Ambrosino, E., *Composition*
453 *of the vaginal microbiota during pregnancy in women living in sub-Saharan Africa: a PRISMA-*
454 *compliant review.* BMC pregnancy and childbirth, 2021. **21**(1): p. 1-15.
- 455 4. Abdool Karim, S.S., Baxter, C., Passmore, J.A.S., McKinnon, L.R. and Williams, B.L., *The genital tract*
456 *and rectal microbiomes: their role in HIV susceptibility and prevention in women.* Journal of the
457 International AIDS Society, 2019. **22**(5): p. e25300.
- 458 5. Charlier, C., O. Disson, and M. Lecuit, *Maternal-neonatal listeriosis.* Virulence, 2020. **11**(1): p. 391-
459 397.
- 460 6. Tumuhamy, J., Steinsland, H., Bwanga, F., Tumwine, J.K., Ndeezi, G., Mukunya, D., et al., *Vaginal*
461 *colonization with antimicrobial-resistant bacteria among women in labor in central Uganda:*
462 *prevalence and associated factors.* Antimicrobial Resistance & Infection Control, 2021. **10**(1): p. 1-
463 11.
- 464 7. Wang, P., Tong, J.J., Ma, X.H., Song, F.L., Fan, L., Guo, C.M., et al., *Serotypes, antibiotic*
465 *susceptibilities, and multi-locus sequence type profiles of Streptococcus agalactiae isolates*
466 *circulating in Beijing, China.* PLoS One, 2015. **10**(3): p. e0120035.
- 467 8. Ozim, C.O., Mahendran, R., Amalan, M. and Puthussery, S., *Prevalence of human*
468 *immunodeficiency virus (HIV) among pregnant women in Nigeria: a systematic review and meta-*
469 *analysis.* 2023. **13**(3): p. e050164.
- 470 9. Manyahi, J., Jullu, B.S., Abuya, M.I., Juma, J., Ndayongeje, J., Kilama, B., et al., *Prevalence of HIV*
471 *and syphilis infections among pregnant women attending antenatal clinics in Tanzania, 2011.* BMC
472 Public Health, 2015. **15**(1): p. 501.
- 473 10. De Goffau, M.C., Lager, S., Sovio, U., Gaccioli, F., Cook, E., Peacock, S.J., et al., *Human placenta has*
474 *no microbiome but can contain potential pathogens.* Nature, 2019. **572**(7769): p. 329-334.
- 475 11. Waldorf, K.M.A. and R.M. McAdams, *Influence of infection during pregnancy on fetal*
476 *development.* Reproduction, 2013. **146**(5): p. R151-R162.
- 477 12. Okwaraji, Y.B., Bradley, E., Ohuma, E.O., Yargawa, J., Suarez-Idueta, L., Requejo, J., et al., *National*
478 *routine data for low birthweight and preterm births: Systematic data quality assessment for*

- 479 *United Nations member states (2000–2020)*. BJOG: An International Journal of Obstetrics &
480 Gynaecology, 2023.
- 481 13. Ohuma, E.O., Moller, A.B., Bradley, E., Chakwera, S., Hussain-Alkhateeb, L., Lewin, A., et al.,
482 *National, regional, and global estimates of preterm birth in 2020, with trends from 2010: a*
483 *systematic analysis*. The Lancet, 2023. **402**(10409): p. 1261-1271.
- 484 14. Birhane Fiseha, S., Mulatu Jara, G., Azerefeqn Woldetsadik, E., Belayneh Bekele, F. and
485 Mohammed Ali, M., *Colonization Rate of Potential Neonatal Disease-Causing Bacteria, Associated*
486 *Factors, and Antimicrobial Susceptibility Profile Among Pregnant Women Attending Government*
487 *Hospitals in Hawassa, Ethiopia*. Infection and Drug Resistance, 2021. **14**: p. 3159.
- 488 15. Kamgobe, E., Grote, S., Mushi, M.F., Wilson, D., Gandye, L., Bader, O., et al., *Multi-drug resistant*
489 *facultative pathogenic bacteria colonizing the vagina of pregnant women with premature rupture*
490 *of membrane, Tanzania*. East Africa Science, 2020. **2**(1): p. 29-35.
- 491 16. Mitima, K.T., Ntamako, S., Birindwa, A.M., Mukanire, N., Kivukuto, J.M., Tsongo, K., *Prevalence of*
492 *colonization by Streptococcus agalactiae among pregnant women in Bukavu, Democratic Republic*
493 *of the Congo*. The Journal of Infection in Developing Countries, 2014. **8**(09): p. 1195-1200.
- 494 17. Ernest, A.I., Ndaboine, E., Massinde, A., Kihunrwa, A. and Mshana, S., *Maternal vaginorectal*
495 *colonization by Group B Streptococcus and Listeria monocytogenes and its risk factors among*
496 *pregnant women attending tertiary hospital in Mwanza, Tanzania*. Tanzania Journal of Health
497 Research, 2015. **17**(2).
- 498 18. Shah, M., Aziz, N., Leva, N. and Cohan, D., *Group B Streptococcus colonization by HIV status in*
499 *pregnant women: prevalence and risk factors*. Journal of women's health, 2011. **20**(11): p. 1737-
500 1741.
- 501 19. Dauby, N., Adler, C., Miendje Deyi, V.Y., Sacheli, R., Busson, L., Chamekh, M., et al. *Prevalence, risk*
502 *factors, and serotype distribution of group B Streptococcus colonization in HIV-infected pregnant*
503 *women living in Belgium: a prospective cohort study*. in *Open Forum Infectious Diseases*. 2018.
504 Oxford University Press US.
- 505 20. Page, M.J., McKenzie, J.E., Bossuyt, P.M., Boutron, I., Hoffmann, T.C., Mulrow, C.D., et al., *The*
506 *PRISMA 2020 statement: an updated guideline for reporting systematic reviews*. International
507 journal of surgery, 2021. **88**: p. 105906.
- 508 21. Schiavo, J.H., *PROSPERO: an international register of systematic review protocols*. Medical
509 reference services quarterly, 2019. **38**(2): p. 171-180.
- 510 22. Wells GA, S.B., O'Connell D, Peterson J, Welch V, Losos M, et al., *The Newcastle-Ottawa Scale*
511 *(NOS) for assessing the quality of nonrandomised studies in meta-analyses*. 2014.
- 512 23. Thompson, D.M. and Y.D. Zhao, *Choosing statistical models to assess biological interaction as a*
513 *departure from additivity of effects*. arXiv preprint arXiv:2301.03349, 2023.
- 514 24. Madrid, L., Maculuve, S.A., Vilajeliu, A., Sáez, E., Massora, S., Cossa, A., et al., *Maternal carriage*
515 *of group B Streptococcus and Escherichia coli in a district hospital in Mozambique*. The Pediatric
516 infectious disease journal, 2018. **37**(11): p. 1145-1153.
- 517 25. Nyemba, D.C., Peters, R.P., Medina-Marino, A., Klausner, J.D., Ngwepe, P., Myer, L., et al., *Impact*
518 *of aetiological screening of sexually transmitted infections during pregnancy on pregnancy*
519 *outcomes in South Africa*. BMC Pregnancy and Childbirth, 2022. **22**(1): p. 194.
- 520 26. Gudza-Mugabe, M., Havyarimana, E., Jaumdally, S., Garson, K.L., Lennard, K., Tarupiwa, A., et al.,
521 *Human immunodeficiency virus infection is associated with preterm delivery independent of*
522 *vaginal microbiota in pregnant African women*. The Journal of infectious diseases, 2020. **221**(7):
523 p. 1194-1203.
- 524 27. Njoku, C., C. Emechebe, and A. Agbakwuru, *prevalence and determinants of anogenital*
525 *colonization by Group B Streptococcus infection among HIV positive and negative women in*
526 *Calabar, Nigeria*. Int J Women's Health Reprod Sci, 2017. **6**(1): p. 11-7.

- 527 28. Price, J.T., Vwalika, B., France, M., Ravel, J., Ma, B., Mwape, H., et al., *HIV-associated vaginal*
528 *microbiome and inflammation predict spontaneous preterm birth in Zambia*. Scientific Reports,
529 2022. **12**(1): p. 8573.
- 530 29. Biobaku Oluwafunmilola, R., Olaleye Atinuke, O., Adefusi Olorunwa, F., Adeyemi Babalola, A.,
531 Onipede Anthony, O., et al., *Group B streptococcus colonization and HIV in pregnancy: A cohort*
532 *study in Nigeria*. Journal of Neonatal-Perinatal Medicine, 2017. **10**(1): p. 91-97.
- 533 30. Smullin, C.P., Green, H., Peters, R., Nyemba, D., Qayiya, Y., Myer, L., et al., *Prevalence and*
534 *incidence of Mycoplasma genitalium in a cohort of HIV-infected and HIV-uninfected pregnant*
535 *women in Cape Town, South Africa*. Sexually transmitted infections, 2020. **96**(7): p. 501-508.
- 536 31. Short, C.E.S., Brown, R.G., Quinlan, R., Lee, Y.S., Smith, A., Marchesi, J.R., et al., *Lactobacillus-*
537 *depleted vaginal microbiota in pregnant women living with HIV-1 infection are associated with*
538 *increased local inflammation and preterm birth*. Frontiers in Cellular and Infection Microbiology,
539 2021. **10**: p. 596917.
- 540 32. Makinde, O., B. Okusanya., and G. Osanyin., *Group B Streptococcus vaginal colonization in*
541 *pregnant women living with HIV infection: prevalence and antibiotic susceptibility at HIV referral*
542 *centers in Lagos, Nigeria*. The Journal of Maternal-Fetal & Neonatal Medicine, 2022. **35**(25): p.
543 9098-9104.
- 544 33. Morgan, J.A., Hankins, M.E., Callais, N.A., Albritton, C.W., Vanchiere, J.A., et al., *Group B*
545 *Streptococcus rectovaginal colonization and resistance patterns in HIV-positive compared to HIV-*
546 *negative pregnant patients*. American Journal of Perinatology, 2023. **40**(14): p. 1573-1578.
- 547 34. Ravindran, J., Richardson, B.A., Kinuthia, J., Unger, J.A., Drake, A.L., Osborn, L., et al., *Chlamydia,*
548 *gonorrhoea, and incident HIV infection during pregnancy predict preterm birth despite treatment*.
549 The Journal of infectious diseases, 2021. **224**(12): p. 2085-2093.
- 550 35. Gray, K.J., Kafulafula, G., Matemba, M., Kamdolozi, M., Membe, G. and French, N., *Group B*
551 *Streptococcus and HIV infection in pregnant women, Malawi, 2008–2010*. Emerging infectious
552 diseases, 2011. **17**(10): p. 1932.
- 553 36. El Beitune, P., Duarte, G., Maffei, C.M.L., Quintana, S.M., Rosa, A.C.J.D.S., Silva, E., et al., *Group B*
554 *Streptococcus carriers among HIV-1 infected pregnant women: prevalence and risk factors*.
555 European Journal of Obstetrics & Gynecology and Reproductive Biology, 2006. **128**(1-2): p. 54-58.
- 556 37. Benedetto, C., Tibaldi, C., Marozio, L., Marini, S., Masuelli, G., Pelissetto, S., et al., *Cervicovaginal*
557 *infections during pregnancy: epidemiological and microbiological aspects*. The Journal of
558 Maternal-Fetal & Neonatal Medicine, 2004. **16**(2): p. 9-12.
- 559 38. Foessleitner, P., Petricevic, L., Boerger, I., Steiner, I., Kiss, H., Rieger, A., et al., *HIV infection as a*
560 *risk factor for vaginal dysbiosis, bacterial vaginosis, and candidosis in pregnancy: A matched*
561 *case-control study*. Birth, 2021. **48**(1): p. 139-146.
- 562 39. Govender, S., Theron, G.B., Odendaal, H.J. and Chalkley, L.J., *Prevalence of genital mycoplasmas,*
563 *ureaplasmas and chlamydia in pregnancy*. Journal of Obstetrics and Gynaecology, 2009. **29**(8): p.
564 698-701.
- 565 40. Zenebe, A., B. Eshetu, and S. Gebremedhin, *Association between maternal HIV infection and*
566 *birthweight in a tertiary hospital in southern Ethiopia: retrospective cohort study*. Italian Journal
567 of Pediatrics, 2020. **46**: p. 1-9.
- 568 41. Joachim, A., Matee, M.I., Massawe, F.A. and Lyamuya, E.F., *Maternal and neonatal colonisation*
569 *of group B streptococcus at Muhimbili National Hospital in Dar es Salaam, Tanzania: prevalence,*
570 *risk factors and antimicrobial resistance*. BMC public Health, 2009. **9**: p. 1-7.
- 571 42. Seale, A.C., Koech, A.C., Sheppard, A.E., Barsosio, H.C., Langat, J., Anyango, E., et al., *Maternal*
572 *colonization with Streptococcus agalactiae and associated stillbirth and neonatal disease in*
573 *coastal Kenya*. Nature microbiology, 2016. **1**(7): p. 1-10.

- 574 43. Temmerman, M., Plummer, F.A., Mirza, N.B., Ndinya-Achola, J.O., Wamola, I.A., Nagelkerke, N.,
575 et al., *Infection with HIV as a risk factor for adverse obstetrical outcome*. *Aids*, 1990. **4**(11): p. 1087-
576 1094.
- 577 44. Cools, P., van de Wijgert, J.H., Jaspers, V., Crucitti, T., Sanders, E.J., Verstraelen, H., et al., *Role of*
578 *HIV exposure and infection in relation to neonatal GBS disease and rectovaginal GBS carriage: a*
579 *systematic review and meta-analysis*. *Scientific Reports*, 2017. **7**(1): p. 13820.
- 580 45. Xiao, P.L., Zhou, Y.B., Chen, Y., Yang, M.X., Song, X.X., Shi, Y., et al., *Association between maternal*
581 *HIV infection and low birth weight and prematurity: a meta-analysis of cohort studies*. *BMC*
582 *pregnancy and childbirth*, 2015. **15**: p. 1-11.
- 583 46. Olaru, I.D., Tacconelli, E., Yeung, S., Ferrand, R.A., Stabler, R.A., Hopkins, H., et al., *The association*
584 *between antimicrobial resistance and HIV infection: a systematic review and meta-analysis*.
585 *Clinical Microbiology and Infection*, 2021. **27**(6): p. 846-853.
- 586 47. Marando, R., Seni, J., Mirambo, M.M., Falgenhauer, L., Moremi, N., Mushi, et al., *Predictors of the*
587 *extended-spectrum-beta lactamases producing Enterobacteriaceae neonatal sepsis at a tertiary*
588 *hospital, Tanzania*. *International Journal of Medical Microbiology*, 2018. **308**(7): p. 803-811.
- 589 48. Kovacs, D., Silago, V., Msanga, D.R., Mshana, S.E., Seni, J., Oravcova, K, et al., *The hospital*
590 *environment versus carriage: Transmission pathways for third-generation cephalosporin-resistant*
591 *bacteria in blood in neonates in a low-resource country healthcare setting*. *Scientific Reports*,
592 2022. **12**(1): p. 8347.


593



medRxiv preprint doi: <https://doi.org/10.1101/2024.09.18.24313939>; this version posted September 19, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license.


S1 Figure PRISMA Flowchart

Figure 2: Interactive Effect of HIV and Bacterial Colonization on Low Birthweight




Random-effects REML model


medRxiv preprint doi: <https://doi.org/10.1101/2024.09.18.24313939>; this version posted September 19, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license.



medRxiv preprint doi: <https://doi.org/10.1101/2024.09.18.24313939>; this version posted September 19, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license.




medRxiv preprint doi: <https://doi.org/10.1101/2024.09.18.24313939>; this version posted September 19, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license.



medRxiv preprint doi: <https://doi.org/10.1101/2024.09.18.24313939>; this version posted September 19, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license.


Log-odds of bacterial colonization with HIV infection versus without HIV





medRxiv preprint doi: <https://doi.org/10.1101/2024.09.18.24913989>; this version posted September 19, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license.


Heterogeneity: $I^2 = 91.1\%$, $p < .0001$
 Test of $\theta = 0$: $z = 0.16$, $p = 0.87$

Random-effects REML model



medRxiv preprint doi: <https://doi.org/10.1101/2024.09.18.24313939>; this version posted September 19, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license.





medRxiv preprint doi: <https://doi.org/10.1101/2024.09.18.24313939>; this version posted September 19, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license.

